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Abstract
Background: Glioblastoma is the most common brain tumor in adults. The mechanisms leading to glioblastoma
are not well understood but animal studies support that inactivation of tumor suppressor genes in neural stem
cells (NSC) is required and sufficient to induce glial cancers. This suggests that the NSC niches in the brain may
harbor cancer stem cells (CSCs), Thus providing novel therapy targets. We hypothesize that higher radiation doses
to these NSC niches improve patient survival by eradicating CSCs.
Methods: 55 adult patients with Grade 3 or Grade 4 glial cancer treated with radiotherapy at UCLA between
February of 2003 and May of 2009 were included in this retrospective study. Using radiation planning software and
patient radiological records, the SVZ and SGL were reconstructed for each of these patients and dosimetry data for
these structures was calculated.
Results: Using Kaplan-Meier analysis we show that patients whose bilateral subventricular zone (SVZ) received
greater than the median SVZ dose (= 43 Gy) had a significant improvement in progression-free survival if
compared to patients who received less than the median dose (15.0 vs 7.2 months PFS; P = 0.028). Furthermore, a
mean dose >43 Gy to the bilateral SVZ yielded a hazard ratio of 0.73 (P = 0.019). Importantly, similarly analyzing
total prescription dose failed to illustrate a statistically significant impact.
Conclusions: Our study leads us to hypothesize that in glioma targeted radiotherapy of the stem cell niches in the
adult brain could yield significant benefits over radiotherapy of the primary tumor mass alone and that damage
caused by smaller fractions of radiation maybe less efficiently detected by the DNA repair mechanisms in CSCs.
Background
Glioblastoma (GB) is the most aggressive form of brain
tumors in adults. The current standard of care combines
surgery and radiotherapy with drug treatment [1,2].
Even with this multi-modality approach, the median sur-
vival is only around 14 months with early recurrences
primarily found in the brain.
Recent preclinical and clinical data provide convincing
evidence that GBs are organized hierarchically with a
small number of cancer stem cells (CSCs), which have
the unique ability to self-renew and exhibit multi-lineage
potency while their progeny lack these features [3-5].
The carcinogenesis of gliomas is still incompletely under-
stood but carcinogenesis in general requires the acquisi-
tion of several mutations of tumor suppressor genes or
oncogenes in normal cells to transform them into malig-
nant tumor cells. In the human brain, the 3-5 mm thick
lateral periventricular region of the lateral ventricles - the
subventricular zone (SVZ) - and a subsection of the hip-
pocampal formation - the subgranular layer (SGL) - have
been shown to harbor normal brain stem cells [6-9].
These regions are believed to contain specific regions of
so-called stem cell niches, which support neuronal stem
cells and keep them in an undifferentiated state. A recent
preclinical study suggested that tumor suppressor gene
deletion in normal neural stem cells (NSCs) but not in
* Correspondence: fpajonk@mednet.ucla.edu
† Contributed equally
1Department of Radiation Oncology, David Geffen School of Medicine at
UCLA, 10833 Le Conte Avenue, Los Angeles, CA-90095, USA
Evers et al. BMC Cancer 2010, 10:384
http://www.biomedcentral.com/1471-2407/10/384
© 2010 Evers et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.their differentiated progeny leads to tumor formation in
the brain [10]. It is suspected that specific niches in the
brain also house CSCs [11] and that CSCs are relatively
resistant to established anti-tumor therapies like radia-
tion [12] and chemotherapy [13]. It has also been shown
that the NSCs in these anatomical niches experience
amplified division under conditions of cortical damage
and their daughter cells (both glial and neuronal) are
routed towards the point of injury, perhaps in a repair
effort, as well as to the contralateral hemisphere [14].
Together, this provides a model by which we can under-
stand how GB recurs bilaterally post-craniotomy as is
often seen clinically [15].
According to the cancer stem cell hypothesis, all CSCs
need to be eliminated in order to cure cancer [16].
Therefore, we hypothesized that the normal tissue stem
cells niche in the brain may be a reservoir for CSCs
from where they initiate and repopulate a tumor and
that irradiation of the potential cancer stem cell niches
in the brain would improve patient survival.
To test our hypothesis we performed a retrospective
analysis of radiation treatment plans of high-grade glioma
patients to study the effect of the radiation dose inadver-
tently delivered to the periventricular stem cells niche on
the progression free survival (PFS) of these patients.
Methods
Patients
55 adult patients with histopathologically diagnosed
grade 3 or grade 4 glial cancer who were treated using
external beam radiation therapy at the University of
California, Los Angeles (UCLA) between February of
2003 and May of 2009 were included in this retrospec-
tive study. The process of patient selection is outlined in
Figure 1. Inclusion criteria were a histopathologically
diagnosed anaplastic glioma (grade 3) or glioblastoma
(grade 4), documented radiological follow-up for at least
1 month after cessation of radiotherapy, and accessible
planning and dosimetry data within UCLAs Radiation
Oncology records. Patients under the age of 18 and
patients who failed to complete full radiotherapy treat-
ment prescription were excluded from the study. This
study was approved by the local Institutional Review
Board at UCLA (IRB# 09-06-081-02).
Contouring
To capture the dosimetry associated with the subjects’
NSC niches, this study required the contouring of the
periventricular (PV) and hippocampal formation (HF)
regions. Contouring the hippocampus was done in
accordance with the protocol outlined by Chera et al
[17]. Based on the operational definitions of the periven-
tricular region, the SVZ was contoured as 3-5 mm lat-
eral margin of the lateral ventricles [18] (Figure 2).
Due to the thin width of the periventricular contour,
Eclipse’s™ (Varian Medical Systems, Palo Alto, CA) post-
processing modification functionality was necessary to
extrapolate the inter-slice volumes and generate a con-
tinuous structure. The average volume of our recon-
structed ipsilateral hippocampal formation was 4.4 cm
3
(95% CI: 4.0-4.8) and 5.05 cm
3 (95% CI: 4.69-5.40) for a
unilateral periventricular region. Dose-volume histo-
grams were calculated and mean dosing was extracted
as the output of interest.
PCR
DNA was isolated from FFPE using Ambion Recoverall
Kit (Applied Biosystems/Ambion, Foster City, CA).
DNA samples were bisulfite-modified using the Zymo
Research EZ-DNA Methylation Gold Kit (Zymo
Research, Orange, CA) according to manufacturer’s
directions. For MGMT, samples were subjected to a
two-stage nested PCR strategy. The first-stage primers
were 5’-GGATATGTTG GGATAGTT-3’ and 5’-CC
AAAAACCCCAAACCC-3’ and second-stage primers
were unmethylated reaction: 5’-TTTGTGTTTTGAT
GTTTGTAGGTTTTTGT-3’ and 5’-AACTCCACACT
CTTCCAAAAACAAAACA-3’; methylated reaction: 5’-
TTTCGACGTTCGTAGGTTTTCGC-3’ and 5’-GCACT
CTTCCGAAAACGAAACG-3’. PCR products were ana-
lyzed on 3% agarose gels.
Statistics
Statistical tests were executed SPSS (version 17; SPSS,
Chicago, Illinois). The primary end-point in this retro-
spective study was PFS as defined as the number of
months after the cessation of radiotherapy until the
establishment of radiological evidence of disease pro-
gression. This establishment of radiological indication of
progression must have been agreed upon by the treating
neurooncologist.
The dosimetry data was extracted as a mean dose
value for each structure of interest: ipsilateral PV, con-
tralateral PV, bilateral PV, and ipsilateral HF. For each
structure, these doses were divided at their median
value into a high dose arm (those patients who received
greater than the median dose) and a low dose arm
(those patients who received a less than median dose).
Kaplan-Meier plots were calculated with event times
being the time since the cessation of therapy until pro-
gression or death, whichever occurred first [19]. Subjects
who neither died nor had cancer progressing were cen-
sored at time of their last follow-up. Patients were strati-
fied based the total prescribed dose and dose delivered
to both periventricular regions.
Relative risks were calculated using the Cox proportional
hazards regression model [20]. Dose to the bilateral peri-
ventricular region was entered as a continuous variable. A
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dose administered, RPA (recursive partitioning analysis)
class, total resection intervention, and tumor location as
construct model effects provided adjusted relative risks
that corresponded to the Kaplan-Meier analyses. The log
partial likelihood was compared with that of a model with-
out interaction in order to test whether the dose to the
periventricular region relative risks differed significantly
with between the low- and the high-dose group. The log
partial likelihood ratio test was used.
Results
The patient population was divided along the median
bilateral periventricular dose (= 43 Gy) into a high dose
group containing 28 subjects, and a low dose group con-
taining 27 subjects. Table 1 illustrates that both groups
were relatively well balanced for the parameters
assessed, except for gender.
Of the 55 subjects evaluated, the median dose to the
bilateral PV was 43 Gy while that to the HF was 47 Gy.
A Kaplan-Meier analysis of the PV dosing illustrated
that the survival curve for those receiving greater than
the median dose of 43 Gy was statistically significantly
different than those who received less than the median
dose (Figure 3). The median PFS for the high PV dose
group was 15 months while the median PFS for the low
PV dose group was 7.2 (p = 0.03, log-rank test). Two
similar Kaplan-Meier analyses of the ipsilateral HF dos-
ing, and ipsilateral PV dosing alone did not yield statisti-
cally significant results.
To assess the simple impact of prescription dose on
PFS in this patient pool, a Kaplan-Meier analysis in
which patients were divided by the median total pre-
scribed dose of 59.4 Gy was analyzed for progression-
free survival, did not yield statistically significant results
(p = 0.83, log-rank test, Figure 4). Likewise, a correlation
analysis between total prescribed dose and bilateral PV
dosing showed only very weak correlation (R
2 = 0.1).
To further quantify the impact of bilateral PV periven-
tricular dosing while controlling for various demo-
graphic characteristics, a Cox regression analysis was
Figure 1 Study subject selection process. “Other”
chemotherapeutics include CPT-11, Carboplatin, CCNU, and
etoposide.
Figure 2 The 2-dimentional CT contouring and resulting 3-dimensional reconstruction.W h i t e :h i p p o c a m p a lf o r m a t i o n .Y e l l o w :
periventricular region. Red: gross tumor volume. Reconstruction image anterosuperior view.
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that includes all patients and models the effects of dose
to the periventricular region, location of the tumor, sur-
gical intervention, RPA classification, and the total pre-
scribed tumor dose as constants over time. Radiation
dose given to the periventricular regions was associated
with decreased risk of progression for patients (relative
risk: 0.74; P = 0.019, 95% CI: 0.567 - 0.951, Cox partial
likelihood ratio test) while the risk ratios for all other
parameters did not reach statistical significance.
Discussion
Even after optimal conventional treatment, the outcome
for patients suffering from GB is currently unacceptable
and drugs like temozolamide add only little survival
benefit for the patients, which comes at very high costs
and is accompanied by considerable toxicity [1]. Pre-
sently, while many other cancers are cured by radiation
treatment, most patients suffering from glioblastoma
relapse after radiotherapy. This is despite the fact that
patients suffering from glioblastoma are generally trea-
ted with relatively high total radiation doses and SF2G y
(surviving fraction at 2 Gy) values for glioblastoma cells
in-vitro are not exceptionally high [21]. A possible
explanation for the failure of radiotherapy to cure
patients from GB is the observation that glioma cells
migrate widely into healthy bilateral brain tissue [22,23]
from one or more foci of origin. These isolated cells are
not detected by current radiological techniques or even
biological imaging and therefore usually not included
into the target volume during radiotherapy.
In our present study we tested the hypothesis that the
dose prescribed to the normal tissue stem cell niche in
the adult brain would impact the effectiveness of radio-
therapy for patients suffering from glioblastoma as these
niches may serve as a harbor for radioresistant glioma
Table 1 Study subject characteristics
# of Subjects
Low PV Dose High PV Dose
Subjects 27 28
Gender Male 18 12
Female 9 16
Mean Age at RT (range) 52 ± 6 (25-82) 51 ± 5 (26-77)
Glioma Grade Grade 3 8 9
Grade 4 19 19
Racial-Ethnicity Caucasian 25 26
Asian 2 2
Surgical Co-Intervention Biopsy-only 2 5
Total Resection 16 6
Subtotal Resection 9 17
Drug Co-intervention Temodar 27 27
Avastin 5 9
Other 8 3
Median Karnofsky Perf. Scale (range) 90% (70-100%) 90% (50-90%)
Mean RPA Classification # of RPA Class III 8 8
# of RPA Class IV 11 8
# of RPA Class V 8 12
MGMT Status Methylated 2 6
Unmethylated 5 6
Unknown 20 16
Tumor Localization Frontal 6 11
Temporal 12 10
Parietal 4 3
Occipital 2 1
Other 3 3
Mean Bilateral PV Dose 27 Gy ± 5 50 Gy ± 2
Median Ipsilateral PV Dose 46 Gy ± 15.5
Median Contralateral PV Dose 41 Gy ± 16.1
Median Ipsilateral HF Dose 49.9 Gy ± 16.3
Mean Total Prescription Dose (range) 52 Gy ± 4 (30-63) 57 Gy ± 2 (45-60)
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believed to able to repopulate a tumor [16]. Our hypoth-
esis was based on previous reports showing that adult
normal tissue stem cells reside in the lateral periventri-
cular regions of the lateral ventricles and the hippocam-
pus [6,9] and animal studies reporting that
transformation of normal tissues stem cells but not dif-
ferentiated cells lead to tumor formation [24-27]. The
unique anatomical patterns of the brain that clearly
separate stem cell niches as a potential pool of CSCs
from differentiated tissue make the brain an ideal model
system to study the impact of radiation dose given to
these stem cell niches.
All but one (54/55) of our patients received radiother-
apy and temozolamide. The mean PFS was 9.6 months
(95% CI: 7.2 - 11.9, Figure 5). We analyzed the PV as a
single bilateral structure given the literature illustrating
that neural stem cells can seed daughter cells along the
distribution pattern of callosal fibers into the contralat-
eral and ipsilateral cortical hemispheres [14,28]. This
process is particularly active in response to cortical
injury, as we would see in conditions of GB. Here we
report that the mean radiation dose applied to both
periventricular regions during fractionated radiotherapy
was correlated with a 108% increase in the median PFS
of patients suffering from glioma (7.2 vs. 15.0 months,
p = 0.03, log-rank test). The mean dose applied to
neither the ipsilateral and contralateral PV region alone
nor the mean dose delivered to the ipsilateral hippocam-
pal region was correlated with prolonged PFS. The fail-
ure of total prescription dose to render statistical
significance in the Cox proportional hazard model as
well as its weak coefficient of determination with PV
dosing excluded prescription dose applied to the tumor
volume as a possible explanation of our data.
Our study has several shortcomings. First, this is a ret-
rospective analysis and as such, it needs validation in a
prospective trial. Second, even though all but one
patient received temozolamide in combination with
radiation, we do not have MGMT (O6-methylguanine-
Figure 4 Kaplan-Meier survival curve illustrating the
progression-free survival difference between those subjects
that received more or less than the median prescription dose
did not yield statistically significant results. p = 0.84, log-rank
test.
Table 2 Cox regression analysis of progression-free
survival
Parameter Risk
Ratio
Lower
CL
Upper
CL
P Variable
Type
Tumor location 1.016 0.77 1.341 0.908 categorical
RPA Class 1.233 0.689 2.206 0.481 categorical
Tumor Resection 0.546 0.228 1.308 0.546 categorical
Periventricular
Dose
0.735 0.567 0.951 0.019 continuous
Total Tumor
Dose
0.794 .451 1.396 0.423 continuous
Figure 3 Kaplan-Meier survival curve illustrating the
progression-free survival difference between those subjects
that received high-dose RT and low-dose RT to their
periventricular regions. p < 0.05, log-rank test.
Figure 5 Kaplan-Meier curve reflecting the overall progression-
free survival of all patients.
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all our patients. Therefore, it is possible that that the
group of patients receiving higher doses to the PV
region had predominantly unmethylated MGMT pro-
moters. Finally, we did not assess the effect of the PV
dose on overall survival because after tumor recurrence
patients were subjected to various salvage therapies. The
heterogeneous nature of the treatments applied would
not have allowed for any conclusions regarding the
radiation treatment and future studies would have to
account for this in the study design.
However, our observation fits well into the current
understanding of neural progenitor cell migratory pat-
terns out of these stem cell niches. In the adult brain,
the SGL NSCs send their differentiated daughter cells
solely into the granular layer of the hippocampus. No
evidence for the SGL distributing cells throughout the
cortex has yet been described. Accordingly, our data
indicating that the magnitude of radiotherapy directed
at the SGL provides no significant impact on progres-
sion is unsurprising. The periventricular SVZ however,
has been shown by Goings et al. to respond to cortical
injury by increasing neurogenesis and sending migratory
cells into the corpus callosum, in the cortex at the edge
of the lesion and on migratory projections between the
lesion and the SVZ [14]. Incorporating this migratory
pattern with the assertions of Llaguno et al. that it is the
NSCs held in the SVZ that hold the malignant transfor-
mation potential to give rise to glioma [10], our data
indicate that efforts to eradicate these SVZ CSCs bilater-
ally may lead to a survival advantage for glioblastoma
patients.
Previous clinical studies prescribing 45 Gy to the nor-
m a lb r a i nw i t ha1 5G yb o o s tf o rt h et u m o rr e g i o nd i d
not yield in significant improvements of clinical out-
come [29]. The major differences between these studies
and our analysis is that the SVZ in our study was mostly
outside the clinical target volume and radiation applied
to the SVZ was therefore given in smaller fractions (1.36
Gy, CI: 1.2 - 1.5). Additionally, radiotherapy techniques
and imaging capabilities have dramatically evolved since
these early trials and therefore, these historic data may
not easily be comparable to modern treatment. The
relative resistance of CSCs to ionizing radiation is
believed to be caused by increased free radical scavenger
expression [30] and activation of DNA damage check-
points [12] in CSCs. We hypothesize that CSCs exhibit
a threshold for DNA damage recognition and damage
caused by subclinical fractions of radiation may remain
undetected by the DNA repair response in CSCs. This is
supported by previous reports describing low dose
hypersensitivity for GB cells [31,32] although low-dose
hypersensitivity has not been studied in CSCs specifi-
cally yet and needs to be addressed in future studies.
Conclusions
In this study, we have illustrated an increase in PFS
among glioblastoma patients when treated with periven-
tricular dosing in excess of 43 Gy. Prescription of a
defined dose to the periventricular region may be a way
to improve treatment responses in patients with high-
grade gliomas. However, the periventricular regions and
the hippocampus are locations of adult neurogenesis
and thought to contribute to normal tissue repair in the
brain. Even though current survival times for most GB
patients are too short to allow the observation of long-
term normal tissue side effects this may change with
improved outcome. Therefore, prospective, randomized
clinical trials should be initiated to address the efficacy
and toxicity of including the periventricular regions as
additional target volumes into treatment plans for
patients suffering from glioblastoma with optimal dosing
yet to be determined.
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